Hybrid lentiviral vectors.
Lentiviral vectors have remarkable cell entry and gene delivery properties that make them highly attractive for gene therapy. However, all integration-competent gene delivery systems have come under scrutiny for possible adverse insertional events. Circumventing the risk of insertional mutagenesis, integration-deficient human immunodeficiency virus (HIV)-1-derived vectors have been shown to support durable transcription of transgenes in certain nonmitotic cell lineages. In mitotic cell populations, such nonintegrated viral forms are lost during cell division and so have time-limited effects. Hybrid lentiviral vectors that harness the cell entry properties of HIV to facilitate carriage of alternative DNA modification systems into cells may allow durable genetic modification with more favorable integration profiles. Thus, systems, which have previously been plasmid-based such as those based on nuclease-enhanced homologous recombination (HR) and artificial transposons, have been incorporated into the viral genome to allow them to "hitch-hike" into cells that are difficult to transfect. Here, we review recent progress in the development of such hybrid lentiviral systems and consider potential applications of such vectors.
Qasim
Waseem
W
Molecular Immunology Unit, Institute of Child Health, University College London, London, UK. w.qasim@ich.ucl.ac.uk
Vink
Conrad A
CA
Thrasher
Adrian J
AJ
D005822:Genetic Vectors / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics; D016086:Lentivirus / Q000235:genetics*; D008957:Models, Genetic
J Clin Invest. 2008 Sep;118(9):3132-42
18688285
Mol Ther. 2009 Jul;17(7):1205-14
19240688
Mol Cell Biol. 2003 Dec;23(23):8505-18
14612396
PLoS One. 2007 Dec 19;2(12):e1340
18092005
Nat Biotechnol. 2007 Nov;25(11):1298-306
17965707
Science. 2009 Nov 6;326(5954):818-23
19892975
Cell. 2005 Aug 12;122(3):473-83
16096065
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17372-7
17090675
Nat Med. 2006 Mar;12(3):348-53
16491086
Mol Cell. 2004 Jan 30;13(2):279-90
14759372
Mol Ther. 2008 Feb;16(2):352-358
28178540
J Biol Chem. 2002 Sep 13;277(37):34581-8
12082109
Nature. 2005 Jun 2;435(7042):646-51
15806097
Mol Ther. 2009 Nov;17(11):1919-28
19672245
J Biol Chem. 2003 Aug 29;278(35):33528-39
12796494
Mol Ther. 2009 Jul;17(7):1197-204
19417741
Mol Cell Biol. 2007 Dec;27(24):8824-33
17938204
Nat Med. 2006 Apr;12(4):401-9
16582916
Genesis. 2009 Jun;47(6):404-8
19391106
Cell. 2002 Aug 23;110(4):521-9
12202041
J Virol. 2001 Sep;75(17):7944-55
11483739
Nat Biotechnol. 2007 Jul;25(7):778-85
17603475
Mol Ther. 2007 Jun;15(6):1137-44
17426709
Mol Ther. 2009 Aug;17(8):1305-6
19644491
Nat Biotechnol. 2008 Jul;26(7):808-16
18587387
PLoS Pathog. 2006 Jun;2(6):e60
16789841
Gene Ther. 2010 Feb;17(2):150-7
19847206
Cell. 1997 Nov 14;91(4):501-10
9390559
J Virol. 1987 Feb;61(2):336-43
3027365
J Clin Invest. 2008 Sep;118(9):3143-50
18688286
Science. 2006 Oct 20;314(5798):461-4
16959972
BMC Biotechnol. 2008 Aug 09;8:60
18691430
Mol Ther. 2007 Dec;15(12):2107-13
17998901
Nat Biotechnol. 2007 Jul;25(7):786-93
17603476
Mol Cell Biol. 2005 Mar;25(6):2085-94
15743807
PLoS Comput Biol. 2006 Nov 24;2(11):e157
17166054
Nature. 2008 Nov 6;456(7218):107-11
18987743
J Virol. 1986 Nov;60(2):683-92
3490582
Nat Biotechnol. 2006 Jun;24(6):687-96
16732270
Mol Ther. 2008 Dec;16(12):1968-76
18797449
Mol Ther. 2002 Nov;6(5):570-1
12409254
Mol Ther. 2007 Nov;15(11):1947-54
17700544
Mol Ther. 2009 May;17(5):844-50
19259065
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18786-91
19843699
Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17684-9
17095605
Mol Ther. 2009 Aug;17(8):1316-32
19491821
Mol Ther. 2006 Jun;13(6):1121-32
16556511
Mol Ther. 2009 Jan;17(1):121-30
18985029
Science. 2003 Oct 17;302(5644):415-9
14564000